Ischemic stroke, defined as a central nervous system injury caused by loss of blood flow, is most often due to arterial thromboembolism. Evaluation should include relevant blood tests and cardiovascular and cardiac investigations (seen in table). Learn more: https://t.co/bQSiiHnizV
Meta-analysis of 5 RCTs (n=4,964): Adding antiplatelet therapy to anticoagulation in chronic coronary syndrome patients offers no benefit for MI, stroke, or MACE—but doubles major bleeding risk. Net clinical outcome significantly worse with dual pathway... https://t.co/qnTmEvmaVT
ATTENTION-LATE: IV TNK + EVT vs EVT Alone in BAO 4.5-24 hrs #ISC26@StrokeAHA_ASA
- baseline NIHSS >10
- exclusion: pre-stroke mRS >2 or PC-aspects <5
- No diff in MRS 0-2 at 90 days between groups, consistent in subgroup analysis
-No diff in secondary efficacy/ safety outcomes
#ISC26@StrokeAHA_ASA
ORIENTAL-MeVO: A positive trial in MeVO space shows that EVT within 24 hrs of sx onset among pts with moderate/high clinical severity improved 90-day functional outcomes without increasing mortality or sICH @RaulNogueiraMD
Bleeding profile favoring DAPT over DOAC + antiplatelet in symptomatic ICAD. What works for CV disease may not work for cerebrovascular disease, c/w CAPTIVA
- advance medical tx by adding Factor XIa, PCSK9, GLP.
- select patients for EVT based on perfusion
https://t.co/wAnHhGvUPp
Stroke Prevention in Moyamoya Syndrome #ISC26
Cilostazol: The New Celebrity in Stroke?
✅️ 23% reduction in mortality
✅️ Incrased CBF and cognition vs clipidogrel
✅️ 6% ischemic recurrence at 5 years
@StrokeAHA_ASA
#ISC26#OPTIONStudy adds further evidence supporting thrombolysis with TNK in the extended 4.5–24h window among cselected non-LVO non-EVT patients with salvageable tissue.
#ISC26#TNKplus: Along with #TIMELESS, patients with MCA LVO and salvageable tissue presenting 4.5–24h from onset, TNK prior to immediate (median 26m) EVT does not improve outcomes compared with EVT alone.
CREST H shows no improvement in cognitive function in pts with asymptomatic stenosis and evidence of hemodynamic impairment. Important information for patients @ESOstroke @WorldStrokeOrg @AANmember
No benefit with addition of TNK to EVT in basilar artery occlusion in the ATTENTION LATE trial. Sharing results of "negative" trials is critical to understanding and building on knowledge gained!
#ISC2026#negativeclinicaltrial#attentionlate@StrokeAHA_ASA
In patients with non–large-vessel occlusion stroke and salvageable tissue, tenecteplase extended to 24 hours improved outcomes compared with standard care but increased bleeding risk.
#ISC26@AHAScience
https://t.co/JWRN5S9QmQ
#ISC2026 day 2, great day for secondary stroke prevention and non-LVO acute ischemic stroke presenting after 4.5 h and have mismatch on perfusion @AHAScience@StrokeAHA_ASA